Tristel (TSTL) Competitors

GBX 408.90 -6.10 (-1.47%)

As of 12:35 PM Eastern

TSTL vs. AMS, SPEC, BVC, AKR, and ODX

Should you be buying Tristel stock or one of its competitors? The main competitors of Tristel include Advanced Medical Solutions Group (AMS), INSPECS Group (SPEC), BATM Advanced Communications (BVC), Akers Biosciences (AKR), and Omega Diagnostics Group (ODX). These companies are all part of the "medical instruments & supplies" industry.

How does Tristel compare to Advanced Medical Solutions Group?

Advanced Medical Solutions Group (LON:AMS) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Advanced Medical Solutions Group currently has a consensus target price of GBX 270.25, suggesting a potential upside of 8.10%. Tristel has a consensus target price of GBX 400, suggesting a potential downside of 2.18%. Given Advanced Medical Solutions Group's stronger consensus rating and higher possible upside, research analysts plainly believe Advanced Medical Solutions Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Medical Solutions Group	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Tristel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

22.6% of Advanced Medical Solutions Group shares are held by institutional investors. Comparatively, 22.0% of Tristel shares are held by institutional investors. 4.1% of Advanced Medical Solutions Group shares are held by company insiders. Comparatively, 21.0% of Tristel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Advanced Medical Solutions Group has a beta of 0.633, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Tristel has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.

In the previous week, Advanced Medical Solutions Group had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for Advanced Medical Solutions Group and 0 mentions for Tristel. Advanced Medical Solutions Group's average media sentiment score of 1.16 beat Tristel's score of 0.00 indicating that Advanced Medical Solutions Group is being referred to more favorably in the media.

Company	Overall Sentiment
Advanced Medical Solutions Group	Positive
Tristel	Neutral

Tristel has a net margin of 15.88% compared to Advanced Medical Solutions Group's net margin of 4.35%. Tristel's return on equity of 23.64% beat Advanced Medical Solutions Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Medical Solutions Group	4.35%	3.87%	2.35%
Tristel	15.88%	23.64%	9.89%

Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.1%. Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.5%. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Advanced Medical Solutions Group has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Medical Solutions Group	£228.94M	2.37	£11.22M	£4.52	55.31
Tristel	£49.54M	3.96	£6.54M	£16.24	25.18

Summary

Advanced Medical Solutions Group beats Tristel on 11 of the 18 factors compared between the two stocks.

How does Tristel compare to INSPECS Group?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -4.25%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
INSPECS Group	-4.25%	-8.73%	0.45%

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	3.96	£6.54M	£16.24	25.18
INSPECS Group	£195.28M	0.44	-£4.11M	-£8.06	N/A

Tristel has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, INSPECS Group has a beta of 1.674, suggesting that its share price is 67% more volatile than the S&P 500.

Tristel currently has a consensus target price of GBX 400, suggesting a potential downside of 2.18%. INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 28.71%. Given Tristel's higher probable upside, equities analysts plainly believe Tristel is more favorable than INSPECS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tristel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

22.0% of Tristel shares are owned by institutional investors. Comparatively, 14.8% of INSPECS Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 21.0% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, INSPECS Group had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for INSPECS Group and 0 mentions for Tristel. Tristel's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company	Overall Sentiment
Tristel	Neutral
INSPECS Group	Neutral

Summary

Tristel beats INSPECS Group on 10 of the 15 factors compared between the two stocks.

How does Tristel compare to BATM Advanced Communications?

Tristel (LON:TSTL) and BATM Advanced Communications (LON:BVC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Tristel currently has a consensus target price of GBX 400, suggesting a potential downside of 2.18%. Given Tristel's higher probable upside, equities research analysts plainly believe Tristel is more favorable than BATM Advanced Communications.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tristel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
BATM Advanced Communications	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Tristel has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, BATM Advanced Communications has a beta of 0.725, suggesting that its stock price is 28% less volatile than the S&P 500.

In the previous week, Tristel's average media sentiment score of 0.00 equaled BATM Advanced Communications'average media sentiment score.

Company	Overall Sentiment
Tristel	Neutral
BATM Advanced Communications	Neutral

Tristel has higher earnings, but lower revenue than BATM Advanced Communications. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£49.54M	3.96	£6.54M	£16.24	25.18
BATM Advanced Communications	£123.20M	0.41	-£278.26K	-£4.20	N/A

22.0% of Tristel shares are owned by institutional investors. Comparatively, 16.9% of BATM Advanced Communications shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 30.4% of BATM Advanced Communications shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tristel has a net margin of 15.88% compared to BATM Advanced Communications' net margin of -14.90%. Tristel's return on equity of 23.64% beat BATM Advanced Communications' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.88%	23.64%	9.89%
BATM Advanced Communications	-14.90%	-22.13%	0.58%

Summary

Tristel beats BATM Advanced Communications on 9 of the 14 factors compared between the two stocks.

How does Tristel compare to Akers Biosciences?

Akers Biosciences (LON:AKR) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Tristel has higher revenue and earnings than Akers Biosciences. Akers Biosciences is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akers Biosciences	£2.32M	0.00	N/A	-£129.60	N/A
Tristel	£49.54M	3.96	£6.54M	£16.24	25.18

Tristel has a net margin of 15.88% compared to Akers Biosciences' net margin of 0.00%. Tristel's return on equity of 23.64% beat Akers Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akers Biosciences	N/A	N/A	N/A
Tristel	15.88%	23.64%	9.89%

22.0% of Tristel shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Akers Biosciences' average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Overall Sentiment
Akers Biosciences	Neutral
Tristel	Neutral

Tristel has a consensus target price of GBX 400, suggesting a potential downside of 2.18%. Given Akers Biosciences' higher probable upside, equities research analysts clearly believe Akers Biosciences is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akers Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tristel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Tristel beats Akers Biosciences on 9 of the 10 factors compared between the two stocks.

How does Tristel compare to Omega Diagnostics Group?

Omega Diagnostics Group (LON:ODX) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Tristel has a net margin of 15.88% compared to Omega Diagnostics Group's net margin of -51.15%. Tristel's return on equity of 23.64% beat Omega Diagnostics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omega Diagnostics Group	-51.15%	-29.14%	-10.53%
Tristel	15.88%	23.64%	9.89%

Omega Diagnostics Group has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500. Comparatively, Tristel has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

In the previous week, Omega Diagnostics Group's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Overall Sentiment
Omega Diagnostics Group	Neutral
Tristel	Neutral

Tristel has higher revenue and earnings than Omega Diagnostics Group. Omega Diagnostics Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omega Diagnostics Group	£7.55M	0.00	-£3.17M	-£0.01	N/A
Tristel	£49.54M	3.96	£6.54M	£16.24	25.18

29.8% of Omega Diagnostics Group shares are held by institutional investors. Comparatively, 22.0% of Tristel shares are held by institutional investors. 50.6% of Omega Diagnostics Group shares are held by company insiders. Comparatively, 21.0% of Tristel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tristel has a consensus target price of GBX 400, indicating a potential downside of 2.18%. Given Omega Diagnostics Group's higher probable upside, analysts clearly believe Omega Diagnostics Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omega Diagnostics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tristel	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Tristel beats Omega Diagnostics Group on 8 of the 12 factors compared between the two stocks.

Get Tristel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSTL vs. The Competition

Export

Metric	Tristel	Medical Instruments & Supplies Industry	Medical Sector	LON Exchange
Market Cap	£195.99M	£2.88B	£6.18B	£2.77B
Dividend Yield	3.46%	2.01%	2.78%	6.15%
P/E Ratio	25.18	16.80	28.73	366.05
Price / Sales	3.96	86.67	507.29	88,619.87
Price / Cash	20.96	146.54	43.30	27.89
Price / Book	5.98	2.59	10.00	7.72
Net Income	£6.54M	£99.80M	£3.54B	£5.89B
1 Month Performance	9.04%	4.93%	4.66%	4.08%
1 Year Performance	4.58%	-6.87%	40.41%	89.87%

Tristel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSTL Tristel	N/A	GBX 408.90 -1.5%	GBX 400 -2.2%	+9.4%	£195.99M	£49.54M	25.18	208	High Trading Volume
AMS Advanced Medical Solutions Group	1.4533 of 5 stars	GBX 243 -1.6%	GBX 270.25 +11.2%	+26.7%	£525.86M	£228.94M	53.76	10	Positive News
SPEC INSPECS Group	0.6131 of 5 stars	GBX 82 -1.8%	GBX 60 -26.8%	+115.8%	£83.37M	£195.28M	N/A	1,673	News Coverage
BVC BATM Advanced Communications	0.6557 of 5 stars	GBX 13.45 -0.4%	N/A	-1.1%	£45.74M	£123.20M	N/A	980
AKR Akers Biosciences	N/A	N/A	N/A	N/A	£21.64M	£2.32M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:TSTL) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tristel (TSTL) Competitors

TSTL vs. AMS, SPEC, BVC, AKR, and ODX

How does Tristel compare to Advanced Medical Solutions Group?

Summary

How does Tristel compare to INSPECS Group?

Summary

How does Tristel compare to BATM Advanced Communications?

Summary

How does Tristel compare to Akers Biosciences?

Summary

How does Tristel compare to Omega Diagnostics Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSTL vs. The Competition

Tristel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tristel (TSTL) Competitors

TSTL vs. AMS, SPEC, BVC, AKR, and ODX

How does Tristel compare to Advanced Medical Solutions Group?

Do analysts recommend AMS or TSTL?

Do insiders and institutionals have more ownership in AMS or TSTL?

Which has more risk & volatility, AMS or TSTL?

Does the media prefer AMS or TSTL?

Is AMS or TSTL more profitable?

Is AMS or TSTL a better dividend stock?

Which has higher earnings & valuation, AMS or TSTL?

Summary

How does Tristel compare to INSPECS Group?

Is TSTL or SPEC more profitable?

Which has higher valuation and earnings, TSTL or SPEC?

Which has more volatility and risk, TSTL or SPEC?

Do analysts recommend TSTL or SPEC?

Do institutionals & insiders have more ownership in TSTL or SPEC?

Does the media favor TSTL or SPEC?

Summary

How does Tristel compare to BATM Advanced Communications?

Do analysts prefer TSTL or BVC?

Which has more risk and volatility, TSTL or BVC?

Does the media favor TSTL or BVC?

Which has better valuation & earnings, TSTL or BVC?

Do insiders and institutionals have more ownership in TSTL or BVC?

Is TSTL or BVC more profitable?

Summary

How does Tristel compare to Akers Biosciences?

Which has higher earnings & valuation, AKR or TSTL?

Is AKR or TSTL more profitable?

Do insiders & institutionals hold more shares of AKR or TSTL?

Does the media refer more to AKR or TSTL?

Do analysts recommend AKR or TSTL?

Summary

How does Tristel compare to Omega Diagnostics Group?

Is ODX or TSTL more profitable?

Which has more risk & volatility, ODX or TSTL?

Does the media prefer ODX or TSTL?

Which has stronger earnings and valuation, ODX or TSTL?

Do insiders & institutionals hold more shares of ODX or TSTL?

Do analysts recommend ODX or TSTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSTL vs. The Competition

Tristel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools